Synthesis and Evaluation of Novel 99m Tc-Labeled Fibroblast Activation Protein Inhibitors Containing Cyclohexane as Promising Tumor Tracers
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c01199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Qing Ruan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (Nationa…. Hauptthemen laut MEDLINE: Membrane Proteins, Cyclohexanes, Radiopharmaceuticals, Gelatinases. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Beijing Nova Program.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) of most solid tumors, and this protein has been a promising target for tumor diagnosis and treatment. Nuclear medicine diagnostic technology has important clinical value for early detection, precise localization and evaluation of treatment effects. To reduce the cost, improve the effectiveness, and increase the scope of use of SPECT radiotracers, a ligand containing cyclohexane as a linker was synthesized, and four 99mTc-labeled FAP inhibitor complexes with different coligands were prepared ([99mTc]Tc-(tricine/TPPTS)-L, [99mTc]Tc-(tricine/TPPMS)-L, [99mTc]Tc-(tricine/PDA)-L, and [99mTc]Tc-(tricine/NIC)-L). In vitro cell experiments revealed that the four complexes specifically bound to cells, and the binding was related to the uptake pathway of FAP; among them, [99mTc]Tc-(tricine/TPPTS)-L showed the best specific uptake. Biodistribution experiments in normal and tumor-bearing mice revealed that [99mTc]Tc-(tricine/TPPTS)-L had relatively low uptake in various nontarget organs and high uptake in U87MG tumors. SPECT/CT imaging revealed obvious uptake in tumors with high FAP expression (U87MG, HT-1080-FAP and HT-29) with a clean background, and no visualization was observed in the tumors of the blocking group (U87MG block, HT-1080-FAP block and HT-29 block) or the tumors with low FAP expression (HT-1080), indicating that the uptake of [99mTc]Tc-(tricine/TPPTS)-L in the tumors had high FAP specificity. Therefore, [99mTc]Tc-(tricine/TPPTS)-L is expected to become a potential tumor molecular probe for clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Norm…
- Key Laboratory of Beam Technology of the Ministry of Education, School of Physics and Astronomy, Beijing Normal University, Beijing 100875, P. R. China.
ORCID-Profile: Qing Ruan, Yuhao Jiang, Junbo Zhang
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Beijing Nova Program
- Science and Technology Innovation Foundation of Dalian
Zitieren
APA
Ruan, Q., Diao, L., Ding, D., Han, P., Yin, G., Jiang, Y., & Zhang, J. (2025). Synthesis and Evaluation of Novel 99m Tc-Labeled Fibroblast Activation Protein Inhibitors Containing Cyclohexane as Promising Tumor Tracers. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01199
Vancouver
Ruan Q, Diao L, Ding D, Han P, Yin G, Jiang Y, et al. Synthesis and Evaluation of Novel 99m Tc-Labeled Fibroblast Activation Protein Inhibitors Containing Cyclohexane as Promising Tumor Tracers. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01199
BibTeX
@article{Ruan2025,
author = {Ruan, Qing and Diao, Lina and Ding, Dajie and Han, Peiwen and Yin, Guangxing and Jiang, Yuhao and Zhang, Junbo},
title = {Synthesis and Evaluation of Novel 99m Tc-Labeled Fibroblast Activation Protein Inhibitors Containing Cyclohexane as Promising Tumor Tracers},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c01199}
}
EUVIMED